ArticleMolecular biomedicine2026
Suppressor with morphogenetic effect on genitalia 7 (SMG7) drives hepatocellular carcinoma progression through context-dependent nonsense-mediated decay (NMD) dysregulation.
Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major risk factor for hepatocellular carcinoma (HCC), yet the molecular mechanisms linking metabolic stress to tumor progression remain poorly defined. RNA surveillance pathways, including nonsense-mediated decay (NMD), may represent a relevant but unexplored regulatory layer in this context. In this study, we analyzed the expression of NMD components across multiple human HCC and MASLD cohorts, identifying suppressor with morphogenetic effect on genitalia 7 (SMG7) as a key regulator of NMD associated with HCC progression. In vitro functional assays, NMD target expression, transcriptomic profiling, and weighted gene co-expression network analysis (WGCNA) were used to identify downstream pathways and mediators. More than 40% of NMD components were dysregulated in HCC. Among them, SMG7 was consistently upregulated across HCC and MASLD cohorts, induced by lipotoxic stress, and identified as a hub gene in HCC transcriptional networks. SMG7 overexpression promoted proliferation, migration, and clonogenicity, whereas its silencing reduced tumor aggressiveness in a context-dependent manner inversely associated with UPF1 levels. Combined depletion of SMG7 and UPF1 suppressed aggressive traits in vitro and limited tumor growth in vivo. Transcriptomic and network analyses identified Z-DNA-binding protein 1 (ZBP1) as a downstream mediator of SMG7 dysregulation in SNU-387 HCC cells, a finding further supported by functional rescue experiments. These results identify the SMG7-ZBP1 axis as a metabolic stress-responsive pathway linking NMD dysfunction to liver tumor progression and highlight NMD modulation as a therapeutic strategy to restrain tumor aggressiveness while enhancing tumor immunogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.